Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies

First Page		Document Content
Date: 2016-07-11 17:03:22 Medicine Clinical medicine Health Rheumatology Inborn errors of purine-pyrimidine metabolism Uric acid Pegloticase Savient pharmaceuticals PEGylation Tophus Gout Allopurinol		Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies Add to Reading List Source URL: www.mvpharm.com Download Document from Source Website File Size: 39,48 KB Share Document on Facebook

	Microsoft Word - Savient Press Release ACRdoc DocID: 1rrcY - View Document
	Microsoft Word - Savient press release re ACRdoc DocID: 1reUR - View Document
	Microsoft Word - Savient press release on ACRdoc DocID: 1pWM3 - View Document
	Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies DocID: 1pRtE - View Document
	Microsoft Word - Savient press release re OLEdoc DocID: 1pDKY - View Document